Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM2PP3
The NM_001319206.4(MEF2A):c.232A>G(p.Ser78Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
MEF2A (HGNC:6993): (myocyte enhancer factor 2A) The protein encoded by this gene is a DNA-binding transcription factor that activates many muscle-specific, growth factor-induced, and stress-induced genes. The encoded protein can act as a homodimer or as a heterodimer and is involved in several cellular processes, including muscle development, neuronal differentiation, cell growth control, and apoptosis. Defects in this gene could be a cause of autosomal dominant coronary artery disease 1 with myocardial infarction (ADCAD1). Several transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2010]
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The c.232A>G (p.S78G) alteration is located in exon 4 (coding exon 2) of the MEF2A gene. This alteration results from a A to G substitution at nucleotide position 232, causing the serine (S) at amino acid position 78 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Loss of phosphorylation at S78 (P = 0.0471);Loss of phosphorylation at S78 (P = 0.0471);Loss of phosphorylation at S78 (P = 0.0471);Loss of phosphorylation at S78 (P = 0.0471);Loss of phosphorylation at S78 (P = 0.0471);